Diagnosis and management of hypersensitivity pneumonitis in adults: A position statement from the Thoracic Society of Australia and New Zealand

2024-12

Barnes, Hayley

Corte, Tamera J

Keir, Gregory

Khor, Yet H

Limaye, Sandhya

Wrobel, Jeremy P

Veitch, Elizabeth

Harrington, John

Dowman, Leona M

Beckert, Lutz

Milne, David

De Losa, Rebekah

Cooper, Wendy A

Bell, Peter T

Balakrishnan, Pradeep

Troy, Lauren K

clinical respiratory medicine

environmental and occupational health and epidemiology

hypersensitivity pneumonitis

inflammation

interstitial lung disease

pulmonary fibrosis

Journal Article

0000-0002-7615-4191

0000-0002-5076-8929

0000-0001-9979-8726

0000-0002-5434-9342

0000-0002-0528-1142

0000-0001-5165-2138

0009-0002-3449-649X

0000-0003-1542-6250

0000-0001-8122-8063

0000-0002-2688-9325

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

0000-0001-5418-4229

0000-0002-0653-0286

0000-0001-5720-052X

0000-0002-7426-336X

10.1111/resp.14847

Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease (ILD) relating to specific occupational, environmental or medication exposures. Disease behaviour is influenced by the nature of exposure and the host response, with varying degrees of lung inflammation and fibrosis seen within individuals. The differentiation of HP from other ILDs is important due to distinct causes, pathophysiology, prognosis and management implications. This Thoracic Society of Australia and New Zealand (TSANZ) position statement aims to provide an up-to-date summary of the evidence for clinicians relating to the diagnosis and management of HP in adults, in the Australian and New Zealand context. This document highlights recent relevant findings and gaps in the literature for which further research is required.

link

Respirology (Carlton, Vic.) 2024-12; 29(12)

Respirology (Carlton, Vic.)